Valiant Laboratories Limited (BOM:543998)
India · Delayed Price · Currency is INR 67.90
-1.08 (-1.57%)
At close: Jun 19, 2026
Valiant Laboratories Revenue
In the fiscal year ending March 31, 2026, Valiant Laboratories had annual revenue of 2.37B INR with 78.04% growth. Valiant Laboratories had revenue of 919.82M in the quarter ending March 31, 2026, with 59.18% growth.
Revenue
2.37B
Revenue Growth
+78.04%
P/S Ratio
1.55
Revenue / Employee
30.06M
Employees
79
Market Cap
3.69B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 2.37B | 1.04B | 78.04% |
| Mar 31, 2025 | 1.33B | -486.75M | -26.74% |
| Mar 31, 2024 | 1.82B | -1.52B | -45.48% |
| Mar 31, 2023 | 3.34B | 215.43M | 6.90% |
| Mar 31, 2022 | 3.12B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Albert David | 3.34B |
| Amanta Healthcare | 2.88B |
| Medico Remedies | 2.06B |
| Medicamen Biotech | 2.01B |
| Everest Organics | 1.97B |
| Gennex Laboratories | 1.73B |
| Jenburkt Pharmaceuticals | 1.69B |
| Kerala Ayurveda | 1.31B |